<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261623</url>
  </required_header>
  <id_info>
    <org_study_id>90921899</org_study_id>
    <nct_id>NCT02261623</nct_id>
  </id_info>
  <brief_title>Prospective, Multi-Center All-Comer Biliary Canadian WallFlex Registry</brief_title>
  <official_title>Prospective, Multi-Center All-Comer Biliary Canadian WallFlex Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to document stent functionality and practice patterns in Canada
      pertaining to indications for use and stent type selection for self-expanding biliary metal
      stents (SEMS) when used per standard of practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to provide a report of these features related to the use of WallFlex
      metal biliary stents used per standard of practice in Canada.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 19, 2015</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Stent Functionality</measure>
    <time_frame>24 Months</time_frame>
    <description>Stent functionality defined as absence of unscheduled biliary reintervention for the management of biliary obstructive symptoms during study stent indwell</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>Occurrence of serious adverse events related to the stent and/or the stent placement and/or stent removal procedures as applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indication for stent placement</measure>
    <time_frame>12 Months</time_frame>
    <description>Distribution of indications for stent placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent types</measure>
    <time_frame>12 Months</time_frame>
    <description>Distribution of stent types by indication for stent placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biliary obstructive symptoms</measure>
    <time_frame>24 Months</time_frame>
    <description>Biliary Obstructive Symptom assessment at all biliary reinterventions compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success at placement</measure>
    <time_frame>24 Months</time_frame>
    <description>Technical success at placement defined as ability to deploy the stent in a satisfactory position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success at removal</measure>
    <time_frame>24 Months</time_frame>
    <description>Technical success at removal (as applicable) defined as ability to remove the stent endoscopically without serious adverse device removal related event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neoadjuvant therapy</measure>
    <time_frame>24 Months</time_frame>
    <description>Ability to complete the planned neoadjuvant therapy regimen without interruptions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stricture resolution</measure>
    <time_frame>24 Months</time_frame>
    <description>Stricture resolution defined as absence of a stricture requiring drainage (restenting) at time of stent removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of original stricture</measure>
    <time_frame>24 Months</time_frame>
    <description>Time to recurrence of original stricture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of the indication for stent placement</measure>
    <time_frame>24 Months</time_frame>
    <description>Resolution of the indication for stent placement</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">415</enrollment>
  <condition>Biliary Strictures</condition>
  <arm_group>
    <arm_group_label>Palliation</arm_group_label>
    <description>Palliative treatment of biliary strictures produced by malignant neoplasms, no intended surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curative intent surgery</arm_group_label>
    <description>Palliative treatment of biliary strictures produced by malignant neoplasms, prior to curative intent surgery, with or without neoadjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign biliary strictures</arm_group_label>
    <description>Treatment of benign biliary strictures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other indication</arm_group_label>
    <description>Other indication</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WallFlex™ Biliary RX Fully Covered Stent System RMV</intervention_name>
    <description>For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures</description>
    <arm_group_label>Palliation</arm_group_label>
    <arm_group_label>Benign biliary strictures</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WallFlex™ Biliary RX Partially Covered Stent System</intervention_name>
    <description>For use in the palliative treatment of biliary strictures produced by malignant neoplasms.</description>
    <arm_group_label>Palliation</arm_group_label>
    <arm_group_label>Curative intent surgery</arm_group_label>
    <arm_group_label>Benign biliary strictures</arm_group_label>
    <arm_group_label>Other indication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WallFlex™ Biliary RX Uncovered Stent System</intervention_name>
    <description>For use in the palliative treatment of biliary strictures produced by malignant neoplasms.</description>
    <arm_group_label>Palliation</arm_group_label>
    <arm_group_label>Curative intent surgery</arm_group_label>
    <arm_group_label>Benign biliary strictures</arm_group_label>
    <arm_group_label>Other indication</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been diagnosed with a blockage of the bile duct which may be caused by a
        benign or malignant biliary stricture.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject indicated for biliary metal stent placement per local standard of practice

          -  Age 18 or older

          -  Willing and able to comply with study procedures and follow-up schedule

          -  Willing and able to provide written informed consent to participate in study

        Exclusion Criteria:

          -  Subjects who are currently enrolled in another investigational study that would
             directly interfere with the current study, without prior written approval from the
             sponsor

          -  Subjects who the investigator deems at risk for device or procedure related
             complications per the Directions for Use (DFU)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gurpal Sandha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peter Lougheed Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health - St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria General Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakville-Trafalgar Memorial Hospital</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 3L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Le Moyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Saint-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS Hotel Dieu</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1K 2R1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

